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SUMMARY 
 
International Circumpolar Surveillance (ICS) is a population-based surveillance system for invasive bacterial 
diseases established in the U.S. Arctic, Northern Canada, Greenland, Iceland, Norway, Finland, and Northern 
Sweden.  Data collection began in 1999 and includes information on disease caused by Streptococcus 
pneumoniae, Haemophilus influenzae, Neisseria meningitidis, and groups A and B Streptococcus (GAS, GBS).  
This report reviews the data collected for the year 2013. 
 
Data on invasive disease with the organism S. pneumoniae are collected from all participating countries.  A total 
of 1,582 cases of invasive pneumococcal disease were identified in 2013.  Overall, rates of invasive S. 
pneumoniae were highest in individuals less than 2 years of age or in persons 65 years and older.  Case fatality 
ratios ranged from 9-16%.  Race and ethnicity data are collected only in N. Canada and the U.S. Arctic; rates of 
invasive pneumococcal disease in Northern Canadian Aboriginal and U.S. Arctic Native populations were 28 
and 35 cases per 100,000 population, respectively, which are similar to the 2012 rates in these populations.  
Pneumonia and bacteremia were the most common clinical presentations; cigarette smoking, alcohol abuse, and 
chronic lung disease were the most common risk factors.  The most common S. pneumoniae serotype in Iceland 
was 19A, in Greenland it was serotypes 4 and 10A, in N. Canada it was serotypes 4 and 7F, in N. Sweden it was 
22F and in the U. S. Arctic the most common serotypes were 16F and 22F. 
 
Data on invasive disease due to H. influenzae, N. meningitidis, and groups A and B Streptococcus are currently 
collected in Greenland, Finland, Northern Canada, Northern Sweden and the U.S. Arctic; Norway also 
contributes data on cases of N. meningitidis and H. influenzae.  A total of 177 H. influenzae cases, 50 N. 
meningitidis cases, 268 GAS cases, and 302 GBS cases were reported in 2013.  In general, the highest rates of 
disease for all organisms occurred in N. Canada Aboriginal or Alaska Native persons less than two years of age 
and persons 65 and older. 
 
Surveillance Organisms Reported by Country, ICS 2013 Data 
 
Country 
S. pneumoniae 
n (rate*) 
H. influenzae 
n (rate*) 
N. meningitidis 
n (rate*) 
GAS 
n (rate*) 
GBS 
n (rate*) 
Finland 724 (13.3) 48 (0.9) 20 (0.4) 181 (3.3) 259 (4.8) 
Greenland 9 (16) 0 (0) 0 (0) 0 (0) 0 (0) 
Iceland 19 (5.9) N/A N/A N/A N/A 
N. Canada 29 (18.4) 19 (12.1) 1 (0.6) 11 (7) 3 (1.9) 
N. Sweden 75 (14.7)† 3 (1.2)‡ 2 (0.8)‡ 23 (9.2)‡ 0 (0)‡ 
Norway 620 (12.3) 86 (1.7) 27 (0.5) N/A N/A 
U.S. Arctic 106 (14.4) 21 (2.9) 0 (0) 53 (7.2) 40 (5.4) 
Total 1,582 (12.9) 177 (1.5) 50 (0.4) 268 (4) 302 (4.5) 
*Cases per 100,000 
† Norbotten & Vasterbotten 
‡Norbotten  
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INTRODUCTION 
 
In January, 1999, the United States and Canada began international cooperative population-based surveillance 
for invasive S. pneumoniae by all laboratories serving residents of the North American Arctic.  In January, 
2000, this surveillance system expanded to include invasive diseases with the following organisms:  H. 
influenzae (all types), N. meningitidis, GAS, and GBS.  These pathogens were selected for ICS because rates of 
these diseases are elevated in indigenous peoples of the north, strains demonstrate resistance to commonly used 
antibiotics, they are routinely cultured in clinical laboratories, and clinically important serotypes of S. 
pneumoniae, H. influenzae, and N. meningitidis are vaccine preventable in infants and adults. 
 
Denmark’s autonomous region of Greenland joined ICS in 2000; Iceland, Norway (including Svalbard), and 
Finland joined in 2001; the Northern Sweden regions of Norbotten and Vasterbotten joined in 2003 and 2006, 
respectively.   
 
GOALS 
 
The goal of ICS is to establish an integrated network of hospital and public health facilities throughout the 
Arctic countries to monitor infectious diseases of concern.  Linking public health facilities within Arctic nations 
will allow for the collection and sharing of uniform laboratory and epidemiological data that will describe the 
prevalence of infectious diseases in Arctic populations and assist in the formulation of prevention and control 
strategies. 
 
The project, initiated in 1998, focused on establishing an ICS system for diseases caused by S. pneumoniae.  
This bacterium causes pneumonia, meningitis, and bacteremia in both the very young and the elderly.  Once 
easily treated with antibiotics, this bacterium has become resistant to commonly used antibiotics.  This is of 
great concern to the public health community and is increasingly a target for surveillance by many countries 
worldwide.  A polysaccharide vaccine is available for use in persons two years of age and older.  A conjugate 
vaccine for infants has been developed and is licensed for use in the U.S., Canada, and the European Union.  
The fact that diseases caused by S. pneumoniae were already being monitored by many public health authorities 
within the Arctic states made establishing a circumpolar surveillance system for this infection feasible.  In 
addition, due to the availability of polysaccharide and conjugate vaccines, much of the morbidity and mortality 
caused by S. pneumoniae is currently preventable. 
 
ICS objectives include: 
 
• Identify key public health contacts within Arctic countries.  These persons should be familiar with infectious 
disease surveillance systems in place (particularly surveillance systems for diseases caused by S. 
pneumoniae) in the member country.  Through correspondence and working group meetings, the scope and 
gaps of the surveillance systems are determined. 
 
• Determine the comparability of laboratory and data collection methods, and negotiate standard protocols 
and quality control programs. 
 
• Share and report data in agreed upon formats. 
 
• Form a working group of key laboratory and public health contacts to coordinate pneumococcal surveillance 
within their respective jurisdictions.  This group meets on a regular basis to review problems, progress, 
compliance, report generation, and future plans. 
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• Form a steering committee of national Arctic health experts to coordinate new objectives and initiatives 
within ICS. 
 
This program forms a framework through which surveillance of other infectious diseases as well as prevention 
and control programs can be added.  Other infectious diseases of circumpolar community concern include:  
other invasive bacterial diseases (caused by H. influenzae, N. meningitidis, GAS, and GBS), tuberculosis, HIV, 
hepatitis, foodborne diseases (botulism, brucellosis), waterborne diseases, respiratory diseases of children such 
as those caused by respiratory syncytial virus, and chronic conditions related to infectious agents (hepatitis B 
virus and liver cancer, human papilloma virus and cervical cancer, H. pylori and stomach cancer), and climate 
sensitive diseases.  In addition, the surveillance model developed by this program for infectious disease may be 
adapted to monitor other non-infectious human health priorities of community concern. 
 
METHODS 
 
ICS is coordinated by personnel at the Arctic Investigations Program (AIP), Centers for Disease Control and 
Prevention, in Anchorage, Alaska. 
 
A case of invasive S. pneumoniae, H. influenzae, N. meningitidis, GAS or GBS is defined by the isolation of the 
bacteria from a normally sterile site, (including blood, cerebrospinal fluid, pleural fluid, peritoneal fluid or joint 
fluid) that has been taken from a resident of the surveillance area. 
 
In the U.S. Arctic and Northern Canada, laboratory, demographic and clinical data are collected continually by 
ICS, while in Greenland, Iceland, Northern Sweden, Norway, and Finland, summary data are submitted to ICS 
in aggregate at the end of the year. 
 
Surveillance System Description by Country/Region 
 
The following table outlines the organisms reported and data provided by each country or region. 
 
Data Provided by Country/Region, ICS 2013 
Country S
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Finland X X X X X  X     X 
Greenland X X X X X X X   X X  
Iceland X     X X   X  X 
N. Canada X X X X X X X X X X X X 
N. Sweden X X X X X  X     X 
Norway X X X    X   X X  
U.S. Arctic X X X X X X X X X X X X 
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Finland 
 
• 23 district hospital laboratories participate in ICS. 
o Provide diagnostic microbiology services for all residents of Finland. 
o All invasive isolates of S. pneumoniae submitted to the National Public Health Institute (KTL) 
laboratory in Oulu. 
 
• Antimicrobial susceptibility testing of S. pneumoniae isolates was performed by agar dilution method at 
district hospital laboratories as well as the KTL laboratory. 
 
• Population estimates for 2013 were obtained from the website http://www.stat.fi  
 
Greenland 
 
• 15 district hospital laboratories participate in ICS. 
o Provide diagnostic microbiology services for all residents of Greenland. 
o All invasive isolates of S. pneumoniae, H. influenzae, N. meningitidis, GAS, and GBS submitted to 
reference laboratories in Nuuk and Copenhagen. 
 
• Antimicrobial susceptibility testing of S. pneumoniae isolates was performed by agar dilution at the central 
laboratory at Queen Ingrid’s Hospital in Nuuk. 
 
• Serotyping was performed at the Statens Serum Institute in Copenhagen, Denmark, by the Quellung 
method. 
 
• Clinical and demographic data for every case of invasive S. pneumoniae, H. influenzae, N. meningitidis, 
GAS, and GBS was collected by public health authorities at the end of the year and entered onto a 
standardized collection tool, the Bacterial Diseases Surveillance Form (BDSF), which is also used in 
Iceland, Northern Canada, and the U.S. Arctic. 
 
• Population estimates for 2013 were obtained from the website http://www.stat.gl  
 
Iceland 
 
• 10 district hospital laboratories and one regional laboratory participate in ICS. 
o Provide diagnostic microbiology services for all residents of Iceland. 
o All invasive isolates of S. pneumoniae submitted to the reference hospital in Reykjavik. 
 
• Antimicrobial susceptibility testing of S. pneumoniae isolates is performed by disc diffusion method at the 
Landspitali University Hospital (LUH) in Reykjavik and the laboratory at the regional hospital in Akureyri.  
All oxacillin resistant isolates are then analyzed by E test. 
 
• Serotyping is performed at the LUH by coagglutination using antisera from Statens Serum Institute. 
 
• Clinical and demographic data for every case of invasive S. pneumoniae was collected by public health 
authorities at the end of the year and entered onto the same collection form (BDSF) used in Greenland, 
Northern Canada, and the U.S. Arctic. 
 
• Population estimates for 2013 were obtained from the website http://www.statice.is  
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Northern Canada 
 
• 14 Canadian laboratories participate in ICS. 
o Provide diagnostic microbiology services for all residents of the Yukon Territory, Northwest Territories, 
Nunavut, Northern Quebec, and Northern Laborador. 
o Submit all invasive isolates of S. pneumoniae, H. influenzae, N. meningitidis, GAS, and GBS to one of 
two reference laboratories in Canada. 
o S. pneumoniae, H. influenzae, GAS, and GBS isolates are serotyped by the Quellung method using 
Statens Serum Institute antisera. 
 
• Antimicrobial susceptibility of S. pneumoniae, GAS, and GBS isolates was tested by micro-broth dilution 
(according to NCCLS recommendations). 
 
• Communicable disease consultants located within one of the five regions of Northern Canada provided 
clinical and demographic information on the same collection form (BDSF) used in Greenland, Iceland, and 
the U.S. Arctic. 
 
• Population estimates for 2013 were obtained from the website http://www.statcan.ca 
 
Northern Sweden 
 
• 1 district laboratory participates in ICS. 
o Provides diagnostic microbiology services for all residents of Norrbotten and Vasterbotten counties. 
o The main reference laboratory is at the Swedish Institute for Infectious Disease Control in Stockholm. 
o Isolates are serotyped by the Quellung method. 
• Antimicrobial susceptibility testing was by disc diffusion at the University Hospital in Umea and Sunderby 
Hospital in Lulea. 
 
• Population estimates for 2013 were obtained from the website http://www.scb.se/default____2154.asp 
 
Norway 
 
• 33 district hospital laboratories participate in ICS. 
o Provide diagnostic microbiology services for all residents of Norway. 
o All invasive isolates of S. pneumoniae submitted to one of two reference laboratories in Oslo or Tromsö. 
 
• Antimicrobial susceptibility testing of S. pneumoniae isolates is performed using the disc diffusion method 
at district hospital laboratories, the reference laboratory in Tromsö or the main national laboratory in Oslo. 
 
• Serotyping is performed at the Statens Serum Institute in Denmark by the Quellung method. 
 
• Population estimates for 2013 were obtained from the website http://www.ssb.no  
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U.S. Arctic 
 
• 23 laboratories providing diagnostic services to residents of Alaska submitted to AIP isolates of S. 
pneumoniae, H. influenzae, N. meningitidis, GAS, and GBS cultured in blood, cerebrospinal fluid, or from 
other sterile sites. 
o S. pneumoniae and H. influenzae isolates are serotyped by the Quellung method using Statens Serum 
Institute antisera. 
o Serogroup testing of N. meningitidis was done using real-time PCR to detect the ctaA gene (capsule 
transport), as well as the genes required for serogroup-specfic capsule biosynthesis.   
 
• Antimicrobial susceptibility testing of S. pneumoniae isolates is performed at AIP by micro-broth dilution 
(according to NCCLS recommendations). 
 
• Clinical and demographic information on each case-patient is recorded by AIP research nurses onto the 
same collection form (BDSF) used in Greenland, Iceland, and Northern Canada. 
 
• Population estimates for 2013 were obtained from the website http://www.labor.state.ak.us 
 
Quality Control 
 
Streptococcus pneumoniae:  Clinical laboratories forward isolates from patients with invasive pneumococcal 
disease to reference laboratories in their respective country.  To ensure inter-laboratory comparability of S. 
pneumoniae serotyping and antimicrobial susceptibility testing between two reference laboratories in Canada 
(Alberta and Quebec) and one in the U.S. (Alaska), the ICS S. pneumoniae inter-laboratory quality control (QC) 
program was established in 1999.  Statens Serum Institute, Copenhagen, Denmark, joined the program in 2004. 
Each reference laboratory is responsible for exporting one QC panel of seven S. pneumoniae isolates every 
other year to each of the other laboratories using a transportation medium of their choice for a total of 14 Strep 
pneumoniae isolates in 2013 [1]. 
 
Neisseria meningitidis/Haemophilus influenzae:  An interlaboratory quality control program for Neisseria 
meningitidis and Haemophilus influenzae was established in 2005.  Participating laboratories include the 
National Microbiology Laboratory, Winnipeg, Manitoba, Canada; Arctic Investigations Program, Anchorage, 
Alaska, USA; Laboratoire Santé Publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada; National 
Centre for Streptococcus, Edmonton, Alberta, Canada; and Statens Serum Institut, Copenhagen, Denmark.  
Strain panels are distributed twice a year from the National Microbiology Laboratory or Arctic Investigations 
Program [2]. 
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Participating Countries, ICS 2013 
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RESULTS 
 
Streptococcus pneumoniae 
 
Case Demographics 
 
A total of 1,582 cases of invasive disease caused by S. pneumoniae were reported to ICS during 2013 by 
Finland, Greenland, Iceland, N. Canada, N. Sweden, Norway, and the U.S. Arctic.  The highest rates of disease 
(18.4 per 100,000) occurred in N. Canada and the lowest in Iceland (5.9 per 100,000) with an overall rate for 
the ICS circumpolar region of 12.9 per 100,000; 54% of all cases occurred in males.  The median age of cases 
overall was 63.3 years with the lowest median age in N. Canada (46.8 years) and the highest in N. Sweden (69 
years).  Case fatality ratios ranged from 9% in Norway to 16% in Iceland and the U.S. Arctic; the overall case 
fatality ratio was 11%. 
 
Streptococcus pneumoniae Case Demographics, ICS 2013 Data 
Country Population 
# 
Cases Rate* 
Sex  
M (%) 
Median Age 
(min-max) yrs 
Deaths 
n (CFR**) 
Finland 5,451,270 724 13.3 403 (56) 62.7 (0-98.1) † 
Greenland 56,370 9 16 5 (56) 51.6 (1.1-64.6) † 
Iceland 321,857 19 5.9 4 (21) 66 (2-92) 3 (16) 
N. Canada 157,602 29 18.4 15 (52) 46.8 (0.4-75.5) 3 (11)b 
N. Sweden 510,415a 75 14.7 34 (45) 69 (0-93) † 
Norway 5,051,275 620 12.3 330 (53) 64.9 (0-96.9) 38 (9)b 
U.S. Arctic 736,399 106 14.4 63 (59) 53.9 (0-97) 17 (16) 
Total 12,285,188 1,582 12.9 854 (54) 63.3 (0-98.1) 61 (11) 
*Number of cases per 100,000 per year 
** Case fatality ratio 
†Case outcomes not reported from Finland, Greenland, N. Sweden 
a Population for Norbotten and Vasterbotten 
b Case outcomes unknown in 1 case from N. Canada, 204 cases from Norway 
 
Streptococcus pneumoniae by Age Category, ICS 2013 Data 
Age  Finland Greenland Iceland N. Canada N. Sweden Norway U.S. Arctic 
<2 yrs 
Pop 118,503 1,549 9,035 5,566 9,844 121,959 21,053 
N (%)* 19 (3) 1 (11) 0 (0) 7 (24) 2 (3) 19 (3) 10 (9) 
Rate† 16 64.6 0 125.8 20.3 15.6 47.5 
2-19 
yrs 
Pop 1,090,064 14,877 80,234 45,619 97,812 1,131,494 187,846 
N (%)* 34 (5) 0 (0) 1 (5) 1 (3) 3 (4) 16 (3) 14 (13) 
Rate† 3.1 0 1.3 2.2 3.1 1.4 7.5 
20-64 
yrs 
Pop 3,186,156 35,791 190,911 96,872 293,253 3,007,208 459,737 
N (%)* 352 (49) 8 (89) 5 (26) 16 (55) 24 (32) 278 (45) 54 (51) 
Rate† 11.1 22.4 2.6 16.5 8.2 9.2 11.8 
65+ 
yrs 
Pop 1,056,547 4,153 41,677 9,545 109,506 790,614 67,763 
N (%)* 319 (44) 0 (0) 13 (68) 5 (17) 46 (61) 307 (50) 28 (26) 
Rate† 30.2 0 31.2 52.4 42 38.8 41.3 
All 
ages 
Pop 5,451,270 56,370 321,857 157,602 510,415 5,051,275 736,399 
N 724 9 19 29 75 620 106 
Rate† 13.3 16 5.9 18.4 14.7 12.3 14.4 
*Proportion of total cases in each country/region 
†Number of cases per 100,000 per year 
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When stratified by age, the highest rates of disease in all countries occurred either in those cases less than two 
years of age or in cases 65+ years of age.   
 
Seasonality 
 
S. pneumoniae was diagnosed throughout the year in 2013 in each country.  For all countries, higher proportions 
of disease were seen in the first and second quarters with declines in the third quarter. Proportions rose again in 
the fourth quarter in all countries except Iceland and N. Canada.  
 
Race 
 
Race and ethnicity data were collected in N. Canada and the U.S. Arctic.  Rates of invasive pneumococcal 
disease were higher overall in Aboriginal and AK Native populations than in non-Aboriginal and non-AK 
Native populations.  The highest rates of disease occurred in Aboriginal and AK Native children less than 2 
years of age in N. Canada and the U.S. Arctic.   
 
Streptococcus pneumoniae by Race and Age Categories, ICS 2013 Data 
Age 
(yrs) 
 
N. Canada† U.S. Arctic 
Aboriginal Non-Aboriginal AK Native Non-AK Native 
<2 Population 4,028 1,538 5,852 15,201 Cases (rate‡) 7 (173.8) 0 (0) 6 (102.5) 4 (26.3) 
2-19 Population 33,515 12,104 50,080 137,766 Cases (rate‡) 1 (3) 0 (0) 9 (18) 5 (3.6) 
20-64 Population 47,331 49,541 77,517 382,220 Cases (rate‡) 13 (27.5) 2 (4) 29 (37.4) 25 (6.5) 
65+ Population 4,714 4,831 9,449 58,314 Cases (rate‡) 4 (84.9) 0 (0) 6 (63.5) 22 (37.7) 
All 
Ages 
Population 89,588 68,014 142,898 593,501 
Cases (rate‡) 25 (27.9) 2 (2.9) 50 (35) 56 (9.4) 
†Race unknown in 2 cases 
‡Number of cases per 100,000 per year 
 
Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each patient’s 
individual medical record associated with the invasive bacterial illness.  In cases with multiple discharge 
diagnoses, the most serious diagnosis related to the pneumococcal infection was recorded as the primary clinical 
presentation.The most common clinical presentations associated with S. pneumoniae were pneumonia, 
bacteremia, and meningitis.  Clinical diagnoses were not reported by Finland and N. Sweden.  In Greenland, N. 
Canada, and the U.S. Arctic the clinical presentation reported most often was pneumonia (44%, 52%, and 62%, 
respectively), in Iceland and Norway it was bacteremia (90% and 53%, respectively).  
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Clinical Presentation of Reported Streptococcus pneumoniae Cases, ICS 2013 Data 
 Greenland 
n (%) 
Iceland 
n (%) 
N Canada 
n (%) 
Norway 
n (%) 
US Arctic 
n (%) 
Pneumonia* 4 (44) 0 (0) 15 (52) 201 (32) 66 (62) 
Bacteremia 3 (33) 17 (89) 11 (38) 328 (53) 21 (20) 
Meningitis 2 (22) 2 (11) 1 (3) 45 (7) 8 (8) 
Empyema 0 (0) 0 (0) 0 (0) 0 (0) 3 (3) 
Peritonitis 0 (0) 0 (0) 0 (0) 0 (0) 3 (3) 
Septic arthritis 0 (0) 0 (0) 0 (0) 3 (0.5) 1 (1) 
Endocarditis 0 (0) 0 (0) 1 (3) 0 (0) 1 (1) 
Pericarditis 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
Cellulitis 0 (0) 0 (0) 1 (3) 0 (0) 1 (1) 
Other 0 (0) 0 (0) 0 (0) 40 (7) 1 (1) 
Unknown 0 (0) 0 (0) 0 (0) 3 (0.5) 0 (0) 
Total Cases 9 19 29 620 106 
*with bacteremia 
 
Risk Factors 
 
N. Canada and the U.S. Arctic reported medical conditions or risk factors associated with S. pneumoniae.  In 
adults 18 years and older, cigarette smoking, chronic lung disease and alcohol abuse were the most commonly 
reported conditions.  
 
Streptococcus pneumoniae Risk Factor/Medical Conditions in Adults*, ICS 2013 Data† 
 N. Canada 
n (%) 
U.S. Arctic 
n (%) 
Cigarette Smoking 8 (36) 27 (33) 
Alcohol Abuse 6 (27) 25 (31) 
Chronic Lung Disease and/or Asthma 5 (23) 24 (29) 
Immunosuppressive Therapy 2 (9) 3 (4) 
Diabetes 3 (14) 10 (12) 
Injection Drug Use 0 (0) 3 (4) 
Asplenia 1 (5) 0 (0) 
Total Adult* Cases 22 82 
*≥ 18 years 
†Multiple risk factors may be reported per case 
 
Vaccination Policy 
 
In Finland, Iceland, N. Canada, Norway, and the U.S. Arctic, 23-valent pneumococcal polysaccharide vaccine 
(PS23) is recommended for persons over 60 years (Iceland) or over 65 years of age (Finland, N. Canada, 
Norway, U.S. Arctic), and for persons greater than two years of age (Finland, Iceland, Norway, U.S. Arctic) or 
greater than five years of age (N. Canada) with specific medical problems.  The vaccine is only recommended 
for certain risk groups in N. Sweden.  Three pneumococcal conjugate vaccines (PCV), PCV7, PCV10, and 
PCV13, for use in children under the age of 2 years have been used in ICS regions since 2001.  Vaccines used 
and years introduced are presented in the table below. 
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Pneumococcal Vaccines Introduced, ICS 2013 Data 
 Finland Greenland Iceland N Canada N Sweden Norway US Arctic 
PCV7    2002-2006* 2007 2007 2001 
PCV10 2010  2011 2009-2010*    
PCV13  2010  2010-2011* 2010 2011 2010 
PS23 † 1996 † 1988 1994 † 1983 
*PCV7 – N Quebec and Nunavut (2002), Newfoundland and Yukon (2005), Northwest Territory (2006); PCV10 – Nunavut (2010); 
PCV13 – N Quebec (2011) 
†PS23 used but year of introduction unknown 
 
Vaccination Status 
 
Seventy-four percent of S. pneumoniae cases in children less than 2 years of age with known vaccination status 
were vaccinated with a PCV in Norway; in the U.S Arctic is was 80% and, in Greenland and N. Canada, 100% 
of children with known vaccine status were vaccinated.  Only 3% of cases eligible for PS23 in Norway were 
vaccinated indicating much less frequent use of this vaccine than in N. Canada and the U.S. Arctic.  Vaccine 
use data were not reported from Finland, Iceland and N. Sweden.   
 
Streptococcus pneumoniae Case Vaccination Status for Pneumococcal Vaccine, ICS 2013 Data 
 
Greenland 
N. 
Canada Norway 
U.S. 
Arctic 
Total cases eligible for PCV vaccine* 1 7 19 10 
Vaccine status known in cases eligible for PCV 1 7 19 10 
Cases eligible for PCV vaccinated (%)† 1 (100%) 7 (100%) 14 (74%) 8 (80%) 
Total cases eligible for PS23 vaccine‡ 0 5 307 28 
Vaccine status known in cases eligible for PS23 N/A 4 95 25 
Cases eligible for PS23 vaccinated (%)† N/A 4 (100%) 3 (3%) 14 (56%) 
*Children less than 2 years of age 
†Percent of vaccine status known cases 
‡Adults 65 years and older 
 
Serotypes 
 
The S. pneumoniae serotypes reported by ICS regions in 2013 are listed in the following table; yellow 
highlights the most common serotypes in each country.  Finland and Norway did not provide serotype data.      
 
 Streptococcus pneumoniae Serotypes by Country, ICS 2013 Data 
Serotype 
Greenland 
n (%) 
Iceland 
n (%) 
N. Canada 
(%) 
N. Sweden* 
n (%) 
U.S. Arctic 
n (%) 
1‡ 1 (11) - - - - 
3‡ 1 (11) - 2 (7) 1 (6) 4 (4) 
4‡ 2 (22) 1 (5) 3 (11) - 1 (1) 
6A‡ - 1 (5) - 1 (6) - 
6B‡ - 1 (5) - - - 
6C - - - 1 (6) 7 (7) 
6D - - 1 (4) - - 
7C - - - - 2 (2) 
7F‡ - 1 (5) 4 (15) 1 (6) 5 (5) 
 12 
Serotype 
Greenland 
n (%) 
Iceland 
n (%) 
N. Canada 
(%) 
N. Sweden* 
n (%) 
U.S. Arctic 
n (%) 
8 - - 2 (7) - 4 (4) 
9N - 1 (5) 1 (4) 2 (13) 3 (3) 
10A 2 (22) - 2 (7) 1 (6) 4 (4) 
11 - 1 (5) - - - 
11A - - - 1 (6) 3 (3) 
12F - - 1 (4) - 6 (6) 
13 - - 1 (4) - - 
14‡ - - - - 1 (1) 
15 - 1 (5) - - - 
15A - - - - 3 (3) 
15B - - - 1 (6) 3 (3) 
15C 1 (11) - - - 3 (3) 
16 - - 1 (4) - - 
16B - - 1 (4) - - 
16F - - 1 (4) - 10 (10) 
17F - - 1 (4) - 3 (3) 
19A‡ - 3 (18) 1 (4) 2 (13) 3 (3) 
19F‡ - 1 (5) - - 1 (1) 
21 - - 1 (4) - - 
22 - 2 (11) - - - 
22F 1 (11) - 2 (7) 3 (19) 13 (13) 
23A - 2 (11) - - 4 (4) 
23B 1 (11) 1 (5) 1 (4) - 4 (4) 
23F‡ - 2 (11) - - - 
31 - - - - 3 (3) 
33F - - 2 (7) 1 (6) 3 (3) 
34 - - 1 (4) - 3 (3) 
35 - 1 (5) - - - 
35B - - - 1 (6) 3 (3) 
Non-viable - - - - 1 (1) 
Total† 9 19 27 16 100 
*Serogroup level data from Vasterbotten 
†Total isolates serotyped 
‡Serotype included in PCV 
 
Cases and Deaths with Vaccine Serotypes 
 
For the countries reporting serotype data, at least 56% of S. pneumoniae cases in persons ≥ 2 years of age had a 
serotype that was included in the 23-valent polysaccharide vaccine.  In children < 2 years of age, only the U.S. 
Arctic had cases with a serotype contained in the PCV13 vaccine.  The proportion of deaths with serotypes in 
the 23-valent polysaccharide vaccine related to S. pneumoniae ranged from 33% to 47%. 
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Proportion of Cases/Deaths with Invasive Pneumococcal Disease Vaccine Serotypes, ICS 2013 Data 
 Greenland 
n/Denom* 
(%) 
Iceland 
n/Denom* 
(%) 
N. Canada 
n/Denom* 
(%) 
N. Sweden 
n/Denom* 
(%) 
U.S. Arctic 
n/Denom* 
(%) 
Cases ≥ 2 years old with serotype in the 
23-valent pneumococcal polysaccharide 
vaccine 
7/8 
(88) 
10/15 
(67) 
15/21 
(71) 
13/16 
(81) 
50/90 
(56) 
Cases < 2 years old with serotype in the 
13-valent pneumococcal conjugate 
vaccine 
0/1 
(0) No cases 
0/6 
(0) 
0/0 
(0) 
2/10 
(20) 
Deaths (all ages) for which the serotype 
was contained in the 23-valent 
pneumococcal vaccine 
0 (0‡) 1 (33‡) 1 (33‡) † 7 (47‡) 
*Number of isolates serotyped by country by age group 
‡Percentage of total death 
†Outcomes not reported 
 
Outcome 
 
A total of 61 deaths associated with S. pneumoniae were reported to ICS in 2013.  Overall, the highest case 
fatality ratio (CFR) occurred in persons 65+ years of age (18%).  Finland, Greenland and N. Sweden did not 
report outcome data. 
 
Streptococcus pneumoniae Age-Specific Case-Fatality Ratios (CFR), ICS 2013 Data 
  <2 years 2-19 years 20-64 years 65+ years All Ages 
Iceland Deaths/Cases* (CFR) 
0/0 
(0%) 
0/1 
(0%) 
0/5 
(0%) 
3/13 
(23%) 
3/19 
(16%) 
N. Canada Deaths/Cases* (CFR) 
1/7 
(14%) 
0/1 
(0%) 
0/15† 
(0%) 
2/5 
(40%) 
3/28 
(11%) 
Norway Deaths/Cases* (CFR) 
0/16† 
(0%) 
1/13† 
(8%) 
6/182† 
(3%) 
31/205 
(15%) 
38/416 
(9%) 
U.S. Arctic Deaths/Cases* (CFR) 
1/10 
(10%) 
2/14 
(14%) 
7/54 
(13%) 
7/28 
(25%) 
17/106 
(16%) 
Total Deaths/Cases* (CFR) 
2/33 
(6%) 
3/28 
(11%) 
13/251 
(5%) 
43/241 
(18%) 
61/553 
(11%) 
*Cases with known outcome.   
†Outcome unknown in (3) Norway cases < 2 years; (3) Norway cases 2-19 years; (1) N Canada, (96) Norway; (153) Norway cases 
65+ years 
 
Antimicrobial Susceptibility 
 
In 2013, antimicrobial susceptibility results were reported to ICS from Finland, Iceland, N. Canada, N. Sweden 
and the U.S. Arctic.  The following table outlines for each country the antibiotics tested, the number of isolates 
reported tested for each antibiotic and the proportion (NS%) of isolates tested that showed any level of non-
susceptibility. 
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Streptococcus pneumoniae Antibiotic Susceptibility Testing, ICS 2013 Data 
 Antibiotic 
Finland 
n (NS%) 
Iceland 
n (NS%) 
N. Canada 
n (NS%) 
N. Sweden 
n (NS%) 
U.S. Arctic 
n (NS%) 
Ceftriaxone - 19 (5%) 27 (0%) - 100 (3%) 
Chloramphenicol - 19 (0%) 25 (0%) - 100 (2%) 
Clindamycin - - 26 (4%) - 100 (4%) 
Erythromycin - 19 (16%) 25 (4%) 38 (0%) 100 (16%) 
Levofloxacin - - 26 (0%) - 100 (0%) 
Penicillin 724 (1%) 19 (16%) 27 (0%) 38 (5%) 100 (13%) 
Tetracycline - - - - 100 (6%) 
TMP Sulfa* - 19 (26%) 27 (0%) 36 (6%) 100 (8%) 
Vancomycin - - 24 (0%) - 100 0%) 
*Trimethoprimsulfamethoxizole 
 
Of the antibiotics tested, the largest numbers of isolates were resistant to penicillin, TMP-Sulfa and 
erythromycin.  Results by country for each of these antibiotics are shown in the tables below.  In the U.S. 
Arctic, 10 isolates comprised of 9 serotypes (3, 6C, 14, 15A, 15B, 19A, 22F, 23A, 35B) showed multi-drug 
resistance.  In Iceland, 3 isolates including serotypes 15, 19A, and 19F were resistant to more than one 
antibiotic.  N. Canada and N. Sweden did not have any multi-drug resistant isolates. Finland did not report 
serotype results.   
 
Streptococcus pneumoniae Penicillin Susceptibility Results, ICS 2013 Data 
 # Tested I* (%) I* Serotypes (n) R* (%) R* Serotypes (n) 
Iceland 19 2 (11%) 15 (1), 19A (1) 1 (5%) 19F (1) 
N. Canada 27 0 (0%)  0 (0%)  
N. Sweden 38 2 (5%) 10A (1), Unk (1) 0 (0%)  
U.S. Arctic 100 11 (11%) 23A (3), 19A (2), 6C (1), 14 (1), 15A (1), 15B (1), 23B (1), 35B (1) 2 (2%) 19A (1), 35B (1) 
*I=Intermediate resistance, R=Fully resistant 
†Serotypes not reported 
 
Streptococcus pneumoniae TMP-Sulfa Susceptibility Results, ICS 2013 Data 
 # Tested I* (%) I* Serotypes (n) R* (%) R* Serotypes (n) 
Iceland 19 1 (5%) 23F (1) 4 (21%) 19A (2), 15 (1), 19F (1) 
N. Canada 27 0 (0%)  0 (0%)  
N. Sweden† 36 1 (3%) Unk (1) 1 (3%) 22F (1) 
U.S. Arctic 100 3 (3%) 6C (1), 15B (1), 23B (1) 5 (5%) 33F (3), 14 (1), 19A (1) 
*I=Intermediate resistance, R=Fully resistant 
†N. Sweden reported serogroups only 
 
Streptococcus pneumoniae Erythromycin Susceptibility Results, ICS 2013 Data 
 # Tested I* (%) I* Serotypes R* (%) R* Serotypes (n) 
Iceland 19 0 (0%)  3 (16%) 15 (1), 19A (1), 19F (1) 
N. Canada 25 0 (0%)  1 (4%) 19A (1) 
N. Sweden 38 0 (0%)  0 (0%)  
U.S. Arctic 100 0 (0%) 
 
16 (16%) 
15A (3), 22F (3), 35B (2), 3 (1), 6C 
(1), 10A (1), 12F (1), 15B (1), 19A 
(1), 23A (1), 31 (1) 
*I=Intermediate resistance, R=Fully resistant 
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Quality Control 
 
In 2013, two QC panels of seven S. pneumoniae isolates plus a control strain each were shipped and tested.  
Beginning in 2005, the MIC data was analyzed in two ways.  The first comparison is based on MIC data 
provided by the distributing laboratory and is the method used historically in the QC program.  The new 
methodology provides an analysis of MIC data for all the participating laboratories by using the modal MIC for 
each antibiotic-organism combination as the value to which the other data are compared.  The modal MIC is the 
MIC most frequently reported.  When two MIC values were reported with equal frequency, both were accepted 
as a modal value.  Antibiotic-organism combinations for which there was no consensus on a modal MIC were 
excluded from the analysis.  The rationale for initiating the second analysis recognizes that there is an allowable 
variation of one log2 dilution inherent for any MIC testing system.  This means that there is no one absolutely 
correct MIC value to which all others can be compared.  The modal MIC may be a better representation of this 
‘true’ value than any one laboratory can provide.  For Panel 2013-A, overall serotyping correlation was 95.6%. 
The modal MIC comparison resulted in an overall correlation of 98.8%.  Overall category agreement was 
96.6% with individual participant agreement ranging from 91.4%-100%.  Chloramphenicol differences 
accounted for 7 out of the 13 categorical errors.  This could be due in part to the fact that there is no 
intermediate range for this antibiotic.  For Panel 2011-B, overall serotyping correlation was 100%.  The modal 
MIC comparison resulted in an overall correlation of 99.7%. Overall category agreement was 97.8% with 
individual participant agreement ranging from 95.3%-100%.   
 
Conclusions 
 
Streptococcus pneumoniae remains a major cause of invasive bacterial disease in circumpolar regions.  Disease 
rates are highest in indigenous populations.  All ICS regions have introduced either PCV10 or PCV13 into their 
vaccine schedules.  Monitoring the impact of these conjugate vaccines will be important to confirm 
effectiveness and provide support for continuing immunization programs. 
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Haemophilus influenzae 
 
Case Demographics 
 
Finland, Greenland, N. Canada, N. Sweden (Norbotten), Norway and the U.S. Arctic reported the occurrence of 
invasive H. influenzae disease during 2013.  A total of 177 cases of invasive disease caused by H. influenzae 
were reported to ICS during 2013.  The highest rate of disease among regions reporting cases was in N. Canada 
(12.1 per 100,000) and the lowest in Finland (0.9/100,000).  Median age of cases was highest in Norway (65.8 
years) and lowest in N. Canada (1.9 years).  Greenland reported no cases in 2013.   
 
Haemophilus influenzae Case Demographics, ICS 2013 Data 
Country Population 
# 
Cases Rate* 
Sex  
M (%) 
Median Age 
(min-max) yrs 
Deaths 
n (CFR†) 
Finland 5,451,270 48 0.9 21 (44) 60.7 (0.5-93.9) ‡ 
Greenland 56,370 0 0 No cases No cases No cases 
N. Canada 157,602 19 12.1 13 (68) 1.9 (0.3-80.1) 2 (11%) 
N. Sweden 249,465 3 1.2 2 (67) 42 (10-89) ‡ 
Norway 5,051,275 86 1.7 38 (44) 65.8 (0-98.2) 10 (18%)‡  
U.S. Arctic 736,399 21 2.9 11 (52) 34.2 (0-86.3) 2 (10%) 
Total 11,702,381 177 1.5 85 (48) 60.5 (0-98.2) 14 (14%) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡ Case outcome unknown in (29) Norway cases; Finland and N. Sweden did not report case outcomes 
 
When stratified by age, the highest rates of disease for N. Canada, Norway and the U.S. Arctic were in the <2 
years age category; in N. Sweden, the highest rate of disease was in the 2-19 year old category and in Finland, 
the highest rate of disease was in the 65+ years age category.   
 
Haemophilus influenzae by Age Category, ICS 2013 Data 
Age  Finland N. Canada N. Sweden Norway U.S. Arctic 
<2 yrs 
Population 118,503 5,566 4,490 121,959 21,053 
Cases (%)* 2 (4) 10 (53) 0 (0) 8 (9) 9 (43) 
Rate† 1.7 179.7 0 6.6 42.8 
2-19 yrs 
Population 1,090,064 45,619 46,659 1,131,494 187,846 
Cases (%)* 3 (6) 5 (26) 1 (33) 2 (2) 0 (0) 
Rate† 0.3 11 2.1 0.2 0 
20-64 yrs 
Population 3,186,156 96,872 141,785 3,007,208 459,737 
Cases (%)* 23 (48) 1 (5) 1 (33) 31 (36) 4 (19) 
Rate† 0.7 1 0.7 1 0.9 
65+ yrs 
Population 1,056,547 9,545 56,531 790,614 67,763 
Cases (%)* 20 (42) 3 (16) 1 (33) 45 (52) 8 (38) 
Rate† 1.9 31.4 1.8 5.7 11.8 
All ages  
Population 5,451,270 157,602 249,465 5,051,275 736,399 
Cases 48 19 3 86 21 
Rate† 0.9 12.1 1.2 1.7 2.9 
*Proportion of total cases in each country/region 
†Number of cases per 100,000 per year 
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Race 
 
Rates of disease were highest in N. Canada Aboriginal (248.1 per 100,000) and U.S. Arctic AK Native (136.7) 
per 100,000) cases less than two years of age.  In both regions, rates of disease were higher in Aboriginal and 
AK Native populations than in non-Aboriginal and non-Native populations in all age categories in which cases 
occurred. 
 
Haemophilus influenzae by Race and Age Categories, ICS 2013 Data 
Age 
(yrs) 
 N. Canada* U.S. Arctic 
Aboriginal Non-Aboriginal AK Native Non-AK Native 
<2 Population 4,028 1,538 5,852 15,201 
 
Cases (rate†) 10 (248.3) 0 (0) 8 (136.7) 1 (6.6) 
2-19 Population 33,515 12,104 50,080 137,766 
 
Cases (rate†) 5 (14.9) 0 (0) 0 (0) 0 (0) 
20-64 Population 47,331 49,541 77,517 382,220 
 
Cases (rate†) 1 (2.1) 0 (0) 2 (2.6) 2 (0.5) 
65+ Population 4,714 4,831 9,449 58,314 
 
Cases (rate†) 3 (63.6) 0 (0) 2 (21.2) 6 (10.3) 
All Ages Population 89,588 68,014 142,898 593,501 
 Cases (rate†) 19 (21.2) 0 (0) 12 (8.4) 9 (1.5) 
*Race unknown in one case <2 years 
†Number of cases per 100,000 per year 
 
Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each patient’s 
individual medical record associated with the invasive bacterial illness.  In cases with multiple discharge 
diagnoses, the most serious diagnosis related to the infection was recorded as the primary clinical presentation. 
In N. Canada, the most common clinical presentation associated with H. influenzae was pneumonia (60% of 
reported cases) followed by meningitis and septic arthritis (21% of cases for each presentation).  In Norway and 
the U.S. Arctic, the most common clinical presentations were bacteremia (49% and 38%, respectively) and 
pneumonia (30% and 38% respectively). Finland and N. Sweden did not report clinical presentation data. 
 
Clinical Presentation of Reported Haemophilus influenzae Cases, ICS 2013 Data 
 N. Canada 
n (%) 
Norway 
n (%) 
U.S. Arctic 
n (%) 
Pneumonia* 7 (37) 26 (30) 8 (38) 
Bacteremia 2 (11) 38 (44) 8 (38) 
Meningitis 4 (21) 8 (9) 4 (19) 
Septic arthritis 4 (21) 0 (0) 0 (0) 
Amnionitis 0 (0) 0 (0) 1 (5) 
Other/Unknown 2 (11) 14 (16) 0 (0) 
Total 19 86 21 
*with bacteremia 
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Risk Factors 
 
Forty-two percent of adult (≥ 18 years) cases of H. influenzae reported in the U.S. Arctic indicated chronic lung 
disease as an associated risk factor; 25% indicated smoking and 8% indicated diabetes and/or alcohol abuse as 
an associated risk factor.  Fifty percent of adult N. Canadian H. influenzae cases reported chronic lung disease 
as a risk factor, 25% reported diabetes, alcohol abuse, and/or immunosuppressive treatment.  Finland, N. 
Sweden and Norway did not report risk factor data. 
 
Vaccination Status 
 
The H. influenzae type b (Hib) conjugate vaccine is required as part of routine childhood vaccination in 
Greenland, N. Canada, N. Sweden, Norway and the U.S. Arctic. There were three cases of Hib reported in a 
child under the age of 5 years in N. Canada (n=1) and the U.S. Arctic (n=2).  The case in N. Canada and one 
case in the U.S. Arctic had received at least one dose of vaccine.  Data on vaccine status were not provided by 
Finland, N. Sweden and Norway. 
 
Haemophilus influenzae Case Vaccination Status for Hib Vaccine, ICS 2013 Data 
 N. Canada U.S. Arctic 
Total cases* eligible for Hib vaccine† 15 9 
Vaccine status known in cases* eligible for Hib vaccine 14 8 
Cases* eligible for Hib vaccine vaccinated (%)‡ 14 (100%) 6 (75%) 
*All serotypes 
†Children less than 5 years of age 
‡Percent of vaccine status known cases 
 
Serotypes 
 
Serotype data were not provided from Finland and N. Sweden. 
 
Haemophilus influenzae Serotypes by Country, ICS 2012 Data 
Serotype N. Canada 
n (%) 
Norway 
n (%) 
U.S. Arctic 
n (%) 
a 16 (89) 0 (0) 5 (24) 
b 1 (6) 3 (4) 2 (10) 
e 0 (0) 1 (1) 0 (0) 
f 0 (0) 17 (22) 3 (14) 
Non-typeable 1 (6) 58 (73) 11 (52) 
Total* 18 79 21 
*Number of isolates serotyped 
 
The most common H. influenzae serotype in N. Canada was type a (77% of cases), in Norway and the US 
Arctic, it was type f (14% and 29% of cases, respectively). Non-typeable cases made up a large proportion of 
cases in Norway (77%) and the U.S. Arctic (43%).  Greenland and N. Sweden did not provide serotype data.  
 
Outcome 
 
Fourteen deaths were associated with H. influenzae cases reported to ICS in 2013; ten from Norway and two 
each from N. Canada and the U.S. Arctic. Finland and N. Sweden did not provide outcome data.   
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Haemophilus influenzae Deaths by Country, ICS 2013 Data 
 N. Canada Norway U.S. Arctic 
No. Deaths 2 10 2 
Case Fatality Ratio 11% 18%* 10% 
Min-max (yrs) 0.9-4.5 0-98.2 0.5-72.7 
Serotypes (n) a (2) f (1), NT (8), unk (1) b (1), NT (1) 
Clinical 
Presentation (n) 
Meningitis (1), 
unknown (1) 
Bacteremia (5) , pneumonia 
(3), meningitis (1), other (1) 
Meningitis (1), 
pneumonia (1) 
*Case outcome unknown in (29) Norway cases 
 
Quality Control 
 
Two QC panels of five H. influenzae and N. meningitidis isolates were shipped and serotyped or serogrouped.  
There was one discrepant result which was due to the primer set available that did not include all possible 
serogroups [2]. 
 
Conclusions 
 
Widespread use of Hib conjugate vaccines has led to the virtual disappearance of Hib disease in these 
populations.  Although serotype a is causing a large proportion of disease in the N. American Arctic, it has not 
reached the rates of Hib disease seen prior to vaccine introduction in these regions.  The proportion of disease 
caused by non-typeable organisms continues to be substantial.   
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Neisseria meningitidis 
 
Case Demographics 
 
Finland, Greenland, N. Canada, N. Sweden (Norbotten), Norway and the U.S. Arctic reported the occurrence of 
N. meningitidis during 2013.  A total of 50 cases of invasive disease caused by N. meningitidis were reported to 
ICS.  Rates were similar in all countries reporting cases ranging from 0.4-0.8 per 100,000.  Two deaths 
associated with N. meningitidis were reported from Norway.  Greenland and the U.S. Arctic reported no cases 
in 2013. 
 
Neisseria meningitidis Case Demographics, ICS 2013 Data 
Country Population 
# 
Cases Rate* 
Sex  
M (%) 
Median Age  
(min-max) yrs 
Deaths 
n (CFR†) 
Finland 5,451,270 20 0.4 8 (40) 17.1 (0.1-87.7) ‡ 
Greenland 56,370 0 0 No cases No cases No cases 
N. Canada 157,602 1 0.6 0 (0) 0.4 (1 case) 0 (0%) 
N. Sweden 249,465 2 0.8 1 (50) 72 (64-80) ‡ 
Norway 5,051,275 27 0.5 13 (48) 25.4 (0-82) 2 (7%) 
U.S. Arctic 736,399 0 0 No cases No cases No cases 
Total 11,702,381 50 0.4 22 (44) 25.9 (0-87.7) 2 (7%) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡Finland and N. Sweden did not report outcomes 
 
The following table shows cases and rates stratified by age category.   
 
  Neisseria meningitidis by Age Category, ICS 2013 Data 
Age  Finland N. Canada N. Sweden Norway 
<2 
yrs 
Population 118,503 5,566 4,490 121,959 
Cases (%)* 7 (35) 1 (100) 0 (0) 4 (15) 
Rate† 5.9 18 0 3.3 
2-19 
yrs 
Population 1,090,064 45,619 46,659 1,131,494 
Cases (%)* 3 (15) 0 (0) 0 (0) 8 (30) 
Rate† 0.3 0 0 0.7 
20-64 
yrs 
Population 3,186,156 96,872 141,785 3,007,208 
Cases (%)* 6 (30) 0 (0) 1 (50) 12 (44) 
Rate† 0.2 0 0.7 0.4 
65+ 
yrs 
Population 1,056,547 9,545 56,531 790,614 
Cases (%)* 4 (20) 0 (0) 1 (50) 3 (11) 
Rate† 0.4 0 1.8 0.4 
All 
ages 
Population 5,451,270 157,602 249,465 5,051,275 
Cases 20 1 2 27 
Rate† 0.4 0.6 0.8 0.5 
*Proportion of total cases in each country/region 
†Number of cases per 100,000 per year 
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Race 
 
In N. Canada, the one case reported in 2013 occurred in an Aboriginal person (rate 1.1/100,000).  
 
Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each patient’s 
individual medical record associated with the invasive meningococcal bacterial illness.  In cases with multiple 
discharge diagnoses, the most serious diagnosis related to the infection was recorded as the primary clinical 
presentation. The most common clinical presentation reported for N. meningitidis cases was meningitis.  
Finland and N. Sweden did not report clinical presentations. 
 
Clinical Presentation of Reported Neisseria meningitidis Cases, ICS 2013 Data 
 N. Canada 
n (%) 
Norway 
n (%) 
Bacteremia 0 (0) 7 (26) 
Meningitis 1 (100) 16 (59) 
Pneumonia 0 (0) 1 (4) 
Other 0 (0) 3 (11) 
Total 1 27 
*with bacteremia 
 
Serogroups  
 
Twenty-six of 50 cases of invasive N. meningitidis reported to ICS in 2013 included serogroup data.  The table 
below lists serogroups by country.  Finland and N. Sweden did not report serogroup data.   
 
Neisseria meningitidis Serogroups by Country, ICS 2013 Data 
Serogroup N. Canada 
n (%) 
Norway 
n (%) 
B - 11 (44) 
C - 6 (24) 
W135 1 (100) 1 (4) 
Y - 7 (28) 
Total 1 25 
 
Conclusions 
 
Neisseria meningitidis is a relatively uncommon cause of invasive bacterial disease in the circumpolar area 
under surveillance, however, continued surveillance is warranted due to high morbidity and mortality associated 
with outbreaks.
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Group A Streptococcus 
 
Case Demographics 
 
Finland, Greenland, N. Canada, N. Sweden (Norbotten) and the U.S. Arctic each reported the occurrence of 
GAS during 2013.  A total of 268 cases of invasive disease caused by GAS were reported to ICS.  Among 
regions reporting cases, the rate of disease was highest in N. Sweden (9.2 per 100,000) compared to the lowest 
in Finland (3.3 per 100,000).  Ten deaths were associated with GAS, seven in the U.S. Arctic and one in N. 
Canada. Greenland reported no GAS cases in 2013. 
 
Group A Streptococcus Case Demographics, ICS 2013 Data 
Country Population # Cases Rate* 
Sex 
M (%) 
Median Age 
(min-max) yrs 
Deaths 
n (CFR†) 
Finland 5,451,270 181 3.3 95 (53) 56.4 (0-96.3) ‡ 
Greenland 56,370 0 0 No cases No cases No cases 
N. Canada 157,602 11 7 8 (73) 41.7 (6.1-85.8) 3 (30%)‡ 
N. Sweden 249,465 23 9.2 10 (44) 52 (5-87) ‡ 
U.S. Arctic 736,399 53 7.2 33 (62) 43 (0.2-84.2) 7 (13%) 
Total 6,651,106 268 4 146 (55) 51.3 (0-96.3) 10 (16%) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡Outcome unknown in (1) N. Canada case; outcomes not reported from Finland and N. Sweden 
 
When stratified by age, the highest rates of disease occurred in children <2 years in the U.S. Arctic (23.8 per 
100,000) and in individuals 65+ years of age in Finland, N. Canada and N. Sweden (6.3 per 100,000, 31.4 per 
100,000 and 14.2 per 100,000, respectively).   
 
Group A Streptococcus by Age Category, ICS 2013 Data 
Age  Finland N. Canada N. Sweden U.S. Arctic 
<2 yrs 
Population 118,503 5,566 4,490 21,053 
Cases (%)* 1 (<1) 0 (0) 0 (0) 5 (9) 
Rate† 0.8 0 0 23.8 
2-19 yrs 
Population 1,090,064 45,619 46,659 187,846 
Cases (%)* 10 (6) 1 (9) 2 (9) 3 (6) 
Rate† 0.9 2.2 4.3 1.6 
20-64 yrs 
Population 3,186,156 96,872 141,785 459,737 
Cases (%)* 103 (57) 7 (64) 13 (57) 39 (74) 
Rate† 3.2 7.2 9.2 8.5 
65+ yrs 
Population 1,056,547 9,545 56,531 67,763 
Cases (%)* 67 (37) 3 (31.4) 8 (35) 6 (11) 
Rate† 6.3 30.1 14.2 8.9 
All ages  
Population 5,451,270 157,602 249,465 736,399 
Cases 181 11 23 53 
Rate† 3.3 7 9.2 7.2 
*Proportion of total cases in each country/region 
†Number of cases per 100,000 per year 
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Race 
 
Race and ethnicity data were collected by N. Canada and the U.S. Arctic.  The highest rates of disease occurred 
in AK Native children <2 years and N. Canada Aboriginal persons 65 years and older. 
 
Group A Streptococcus by Race and Age Categories, ICS 2013 Data 
Age 
(yrs) 
 N. Canada U.S. Arctic 
Aboriginal Non-Aboriginal AK Native Non-AK Native 
<2 Population 4,028 1,538 5,852 15,201 Cases (rate†) 0 (0) 0 (0) 5 (85.4) 0 (0) 
2-19 Population 33,515 12,104 50,080 137,766 Cases (rate†) 0 (0) 1 (8.3) 2 (4) 1 (0.7) 
20-64 Population 47,331 49,541 77,517 382,220 
 
Cases (rate†) 6 (12.7) 0 (0) 17 (21.9) 22 (5.7) 
65+ Population 4,714 4,831 9,449 58,314 
 
Cases (rate†) 3 (63.6) 0 (0) 0 (0) 6 (10.3) 
All Ages Population 89,588 68,014 142,898 593,501 
 Cases (rate†) 9 (10.1) 1 (1.5) 24 (16.8) 29 (4.9) 
†Number of cases per 100,000 per year 
 
Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each patient’s 
individual medical record associated with the invasive bacterial illness.  In cases with multiple discharge 
diagnoses, the most serious diagnosis related to the infection was recorded as the primary clinical presentation.  
The most common clinical presentation for GAS cases in N. Canada and the U.S. Arctic was bacteremia. 
Finland and N. Sweden did not report clinical presentations.     
 
Clinical Presentation of Reported group A Streptococcus Cases, ICS 2013 Data 
 N. Canada 
n (%) 
U.S. Arctic 
n (%) 
Bacteremia 3 (27) 17 (32) 
Cellulitis* 1 (9) 11 (21) 
Necrotizing fasciitis 2 (18) 6 (11) 
Pneumonia* 0 (0) 9 (17) 
Septic arthritis 2 (18) 3 (6) 
Empyema 0 (0) 2 (4) 
Endocarditis 0 (0) 1 (2) 
Strep toxic shock 1 (9) 0 (0) 
Peritonitis 0 (0) 1 (2) 
Endometritis 0 (0) 1 (2) 
Other/Unknown 2 (18) 2 (4) 
Total 11 53 
*with bacteremia 
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Risk Factors 
 
Cigarette smoking, alcohol abuse and diabetes were the most common risk factors associated with adult (≥18 
years) GAS cases in the U.S. Arctic; in N. Canada alcohol abuse, chronic lung disease and diabetes were most 
commonly reported. Finland, Greenland and N. Sweden did not report risk factor data. 
 
Group A Streptococcus Risk Factor/Medical Conditions in Adults*, ICS 2013 Data† 
 N. Canada 
n (%) 
U.S. Arctic 
n (%) 
Cigarette Smoking 1 (10) 14 (26) 
Alcohol Abuse 2 (20) 10 (19) 
Chronic Lung Disease and/or Asthma 2 (20) 7 (13) 
Immunosuppressive Therapy 0 (0) 0 (0) 
Diabetes 2 (20) 11 (21) 
Injection Drug Use 0 (0) 4 (8) 
Asplenia 0 (0) 2 (4) 
Total Adult* Cases 10 53 
*≥ 18 years 
†Multiple risk factors may be reported per case 
 
Outcome 
 
Seven deaths in cases with GAS were reported from the U.S. Arctic (CFR 13%); one occurred in the 2-19 years 
old age category, three in the 20-64 age category and three in persons ≥ 65.  One death was reported in Canada 
in the 20-64 age category and two in persons 65 years of age and older. Finland and N. Sweden did not report 
case outcome data. 
 
Conclusions 
 
These data suggest higher rates in indigenous populations, particularly in young children and older adults.  
Increased awareness of risk may help target improved treatment responses. 
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Group B Streptococcus 
 
Case Demographics 
 
Finland, Greenland, N. Canada, N. Sweden and the U.S. Arctic each reported the occurrence of GBS during 
2013.  A total of 302 cases of invasive disease caused by GBS were reported to ICS.  Greenland and N. Sweden 
reported no cases. One death in the U.S. Arctic was associated with GBS in 2013. 
 
Group B Streptococcus Case Demographics, ICS 2013 Data 
Country Population 
# 
Cases Rate* 
Sex 
M (%) 
Median Age 
(min-max) yrs 
Deaths 
n (CFR†) 
Finland 5,451,270 259 4.8 112 (43) 64.8 (0-96.1) ‡ 
Greenland 56,370 0 0 No cases No cases No cases 
N. Canada 157,602 3 1.9 1 (33) 0 (0-58.2) 0 (0) 
N. Sweden 249,465 0 0 No cases No cases No cases 
U.S. Arctic 736,399 40 5.4 17 (43) 59.4 (0-84.9) 1 (3) 
Total 6,651,106 302 4.5 130 (43) 63.8 (0-96.1) 1 (2) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡Outcomes not reported 
 
When stratified by age, the highest rates of disease in all countries reporting cases occurred in children less than 
two years of age.   
 
Group B Streptococcus by Age Category, ICS 2013 Data 
Age  Finland N. Canada U.S. Arctic 
<2 yrs 
Population 118,503 5,566 21,053 
Cases (%)* 33 (13) 2 (67) 6 (15) 
Rate† 27.9 35.9 28.5 
2-19 yrs 
Population 1,090,064 45,619 187,846 
Cases (%)* 0 (0) 0 (0) 0 (0) 
Rate† 0 0 0 
20-64 yrs 
Population 3,186,156 96,872 459,737 
Cases (%)* 97 (38) 1 (33) 19 (48) 
Rate† 3 1 4.1 
65+ yrs 
Population 1,056,547 9,545 67,673 
Cases (%)* 129 (50) 0 (0) 15 (38) 
Rate† 12.2 0 22.1 
All ages  
Population 5,451,270 157,602 736,399 
Cases 259 3 40 
Rate† 4.8 1.9 5.4 
*Proportion of total cases in each country/region 
†Number of cases per 100,000 per year 
 
There were three cases of early-onset disease (cases less than 7 days old) in the U.S. Arctic and 2 cases in N. 
Canada (0.3 and 0.7 cases per 1,000 live births respectively). 
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Race 
 
Race and ethnicity data were collected in N. Canada and the U.S. Arctic.  The overall rates of disease caused by 
GBS were higher in AK Native people compared to non-Native people.  The highest rates of disease occurred in 
N. Canada Aboriginal and Alaska non-Native children less than 2 years old. 
 
Group B Streptococcus by Race and Age Categories, ICS 2013 Data 
Age 
(yrs) 
 N. Canada U.S. Arctic 
Aboriginal Non-Aboriginal AK Native Non-AK Native 
<2 Population 4,028 1,538 5,852 15,201 Cases (rate†) 2 (49.7) 0 (0) 1 (17.1) 5 (32.9) 
2-19 Population 33,515 12.104 50,080 137,766 Cases (rate†) 0 (0) 0 (0) 0 (0) 0 (0) 
20-64 Population 47,331 49,541 77,517 382,220 
 
Cases (rate†) 1 (2.1) 0 (0) 6 (7.7) 13 (3.4) 
65+ Population 4,714 4,831 9,449 58,314 
 
Cases (rate†) 0 (0) 0 (0) 3 (31.8) 12 (20.6) 
All Ages Population 89,588 68,014 142,898 593,501 
 Cases (rate†) 3 (3.4) 0 (0) 10 (7) 30 (5.1) 
†Number of cases per 100,000 per year 
 
Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each patient’s 
individual medical record associated with the invasive bacterial illness.  In cases with multiple discharge 
diagnoses, the most serious diagnosis related to the infection was recorded as the primary clinical presentation.  
In N. Canada and the U.S. Arctic, bacteremia (67% and 40%, respectively) was the most common clinical 
presentation reported for cases of GBS in 2013. Finland did not report clinical presentations.  
 
Clinical Presentation of Reported group B Streptococcus Cases, ICS 2013 Data 
 N. Canada 
n (%) 
U.S. Arctic 
n (%) 
Bacteremia 2 (67) 16 (40) 
Cellulitis* 0 (0) 11 (28) 
Pneumonia* 0 (0) 3 (8) 
Septic arthritis 0 (0) 1 (2.5) 
Amnionitis 0 (0) 1 (2.5) 
Endocarditis 0 (0) 2 (5) 
Meningitis 1 (33) 1 (2.5) 
Necrotizing fasciitis 0 (0) 1 (2.5) 
Peritonitis 0 (0) 1 (2.5) 
Other 0 (0) 3 (8) 
Total 3 40 
*with bacteremia 
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Risk Factors 
 
Thirty-eight percent of GBS adult (≥ 18 years) cases reviewed in the U.S. Arctic indicated diabetes as a risk 
factor in 2013; 15% had chronic lung disease and 12% reported alcohol abuse.  The one adult case in N. Canada 
reported no risk factors.   
 
 
Outcome 
 
One death in cases with GBS was reported in the U.S. Arctic (CFR 3%); the death occurred in the 65+ years age 
category.   
 
Conclusions 
 
Guidelines for universal screening of pregnant women for GBS carriage were established in 2002 which have 
resulted in decreases in early onset disease.  Cases continue to occur in older age groups which warrants 
continued surveillance.
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CONCLUSIONS 
 
Monitoring rates of disease and levels of antimicrobial resistance in S. pneumoniae, H. influenzae, N. 
meningitidis, GAS and GBS via use of the ICS system is important in providing data on groups at risk for 
disease, measurement of effectiveness of prevention measures, and emerging challenges in serotype distribution 
and antimicrobial resistance.  Efforts to expand ICS to include all circumpolar nations will continue. 
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PARTICIPANTS 
 
International Circumpolar Surveillance (ICS) Participants, 2012 
 
FINLAND 
Reference 
Laboratory 
National Public Health Institute (KTL) Laboratory, Oulu 
Laboratories Et.-Pohjanmaan sh-piiri, Seinäjoen sairaalan mikrobiol. lab. 
Etelä-Karjalan keskussairaalan kl.mikrobiologian laboratorio 
HY – Serobakteriologian laitos 
Jorvin sairaala, kliinisen mikrobiologian laboratorio 
KYS – Mikrobiologian laboratorio 
Kainuun keskussairaalan mikrobiologian laboratorio 
Kanta-Hämeen keskussairaalan mikrobiologian laboratorio 
Keski-Pohjanmaan keskussairaalan mikrobiologian laboratorio 
Keski-Suomen keskussairaalan mikrobiologian laboratorio 
Kymenlaakson keskussairaalan mikrobiologian laboratorio 
Lapin keskussairaalan mikrobiologian laboratorio 
Länsi-Pohjan keskussairaalan laboratorio 
Mikkelin keskussairaalan mikrobiologian laboratorio 
OYKS – Mikrobiologian laboratorio 
Oulun kiakonissalairoksen laboratorio 
Pohjois-Karjalan keskussairaalan mikrobiologian laboratorio 
Päijät-Hämeen keskussairaalan mikrobiologian laboratorio 
Rauman aluesairaalan laboratorio 
Satakunnan keskussairaalan mikrobiologian laboratorio 
Savonlinnan keskussairaalan laboratorio 
TAYS – Mikrobiologian laboratorio 
TYKS – Mikrobiologian laboratorio 
Vaasan keskussairaalan mikrobiologian laboratorio 
 
GREENLAND 
Reference 
Laboratories 
Statens Serum Institute, Copenhagen, Denmark 
Centralab at Queen Ingrid’s Hospital, Nuuk, Greenland 
Laboratories Nanortalik Hospital 
Qaqortoq Hospital 
Narsaq Hospital 
Paamiut Hospital 
Maniitsoq Hospital 
Sisimut Hospital 
Aasiaat Hospital 
Qasigiannguit Hospital 
Ilulissat Hospital 
Qeqertarsuaq Hospital 
Uummannaq Hospital 
Upernavik Hospital 
Qaanaaq Hospital 
Ammassalik Hospital 
Ittoqqortoormiit Hospital 
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ICELAND 
Reference 
Laboratory 
Department of Microbiology, Landspitali University Hospital, 
Reykjavik 
Laboratories Akranes Hospital 
Isafjordur District Hospital 
Stykkisholmur Local Health Center 
St. Joseph’s Hospital Hafnarfjorour 
Municipal Hospital of Vestmannaeyjar 
Akureyri 
Egilstadir Health Center 
Selfoss Health Center 
Sudurnes Health Center (Keflavik) 
Regional Hospital Neskaupstadur 
 
NORTHERN CANADA 
Laboratory Centre 
for Disease Control 
Respiratory Division, Bureau of Infectious Diseases, Laboratory 
Centre for Disease Control, Ottawa 
Reference 
Laboratories 
National Centre for Streptococcus, Provincial Laboratory of Public 
Health, Edmonton, AB 
Laboratoire de Santé Publique du Québec, Montréal, QC 
National Centre for Meningococcus, Provincial Laboratory of Public 
Health, Winnipeg, MB 
Laboratories Whitehorse General Hospital, Whitehorse, YK 
Stanton Regional Health Board, Yellowknife, NT 
H.H. Williams Memorial Hospital, Hay River, NT 
Inuvik Regional Hospital, Inuvik, NT 
Baffin Regional Hospital, Iqaluit, NU 
Churchill Regional Health Authority, Churchill, MB 
Cadham Provincial Laboratory, Winnipeg, MB 
Ungava Tulattavik Health Centre, Kuujjuaq, QC 
Inulitsavik Hospital, Puvirnituq, QC 
Cree Health Board, Chisasibi, QC 
CSSSR, Chibougamou, QC 
Val d’Or Hospital, Val d’Or, QC 
Melville Hospital, Goose Bay, NL 
Newfoundland Public Health Laboratory, St. John’s, NL 
Public Health Yukon Communicable Disease Control, Whitehorse, YK 
Health Protection Unit, Government of NWT, Yellowknife, NT 
JA Hildes Northern Medical Unit, Winnipeg, MB 
Régie Régionale de la Santé et des Services Sociaux, Kuujjuaq, QC 
Région Cri de la Baie James, Module de Santé Publique, Montreal, 
QC 
Communicable Disease Control, Health Laborador Corporation, 
Goose Bay, NL 
IMPAct Coordinator, Vaccine Evaluation Centre, Vancouver, BC 
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NORTHERN SWEDEN 
Reference 
Laboratory 
Department of Bacteriology, Swedish Institute for Infectious Disease 
Control, Stockholm 
Laboratories Department of Microbiology, Sunderby Hospital, Lulea 
 
NORWAY 
Reference 
Laboratory 
Oslo/Tromsö 
Laboratories Frederikstad, Østf. SSH 
Sarpsborg SH 
Akershus SSH, SiA 
Bœrum SH 
Aker SH 
Fürsts laborat, Oslo 
Dr. Willes med.lab. 
Radiumhospitalet 
Folkehelsa, vir.lab. 
Folkehelsa, bakt.lab. 
Forsv.mik.lab.Folk.h. 
Rikshospitalet, mik.lab. 
Ullevål SH, mik.lab. 
Lab. klin. mikrob. Oslo 
Lillehammer mik.lab 
Elverum mik.lab. 
Buskerud SSH, mik.lab. 
Vestfold SSH, mik.lab. 
Telelab 
Vest-Agder SSH, mik.lab. 
Rogaland SSH, mik.lab. 
Haukeland SH, mik.lab. 
Sogn-Fk. SSH, mik.lab. 
Ålesund FSH, mik.lab. 
Molde FSH, mik.lab. 
Trondheim RSH, mik.lab. 
Innherred SH, mik.lab. 
Namdal SH, mik.lab. 
Nordland SSH, mik.lab. 
Tromsø RSH, mik.lab. 
Kirkenes SH, mik.lab. 
Laboratorium INA/div. 
Haugesund, mik.lab. 
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U.S. ARCTIC 
Reference 
Laboratory 
Arctic Investigations Program, National Center for Emerging and 
Zoonotic Infectious Diseases, Centers for Disease Control and 
Prevention, Anchorage, AK 
Laboratories Alaska Native Medical Center, Anchorage, AK 
Alaska Regional Hospital, Anchorage, AK 
Bartlett Regional Hospital, Juneau, AK 
Bassett Army Hospital, Fort Wainwright, AK 
Central Peninsula General Hospital, Soldotna, AK 
Cordova Community Medical Center, Cordova, AK 
Elmendorf Air Force Base Hospital, Anchorage, AK 
Fairbanks Memorial Hospital, Fairbanks, AK 
Kanakanak Hospital, Dillingham, AK 
Ketchikan Regional Hospital, Ketchikan, AK 
Manilaq Medical Center, Kotzebue, AK 
Norton Sound Regional Hospital, Nome, AK 
Petersburg Medical Center, Petersburg, AK 
Providence Alaska Medical Center, Anchorage, AK 
Providence Island Medical Center, Kodiak, AK 
Samuel Simmonds Memorial Hospital, Barrow, AK 
Sitka Community Hospital, Sitka, AK 
South Peninsula Hospital, Homer, AK 
Southeast Area Regional Health Corporation, Sitka, AK 
State Public Health Laboratory, Division of Public Health, 
Department of Health and Social Services, Anchorage, AK 
Valdez Community Hospital, Valdez, AK 
Valley Hospital, Palmer, AK 
Wrangell General Hospital, Wrangell, AK 
Yukon-Kuskokwim Delta Regional Hospital, Bethel, AK 
 
